Top Orlistat Brands to Boost Your Weight Loss Journey

Orlistat, a popular weight loss medication, has carved its niche in the market with various brands offering their own versions. Different brands stand out for their quality, efficacy, and affordability, catering to diverse consumer needs. While some brands are renowned for their long-standing reputation, others are praised for innovative formulations or convenient purchasing options. To explore the top brands that offer orlistat and understand what sets them apart, take a look below.

Illustration of orlistat

Best brands of orlistat in 2025

Xenical by Roche

Xenical, produced by Roche, is a highly effective lipase inhibitor for obesity management, acting by inhibiting the absorption of dietary fats. In clinical studies, 40% of patients treated with Xenical achieved a weight loss of >=5% of their baseline body weight, and 21% lost more than 10% of their body weight over a four-year period, significantly outperforming placebo groups. The medication is indicated for obese patients with a BMI >=30 kg/m2 or overweight patients with associated risk factors. Xenical was granted marketing authorisation by the European Commission in 1998 and has been renewed multiple times since then. It is available as 120 mg turquoise capsules.

Alli by GlaxoSmithKline

Alli, produced by GlaxoSmithKline, is the first and only FDA-approved over-the-counter (OTC) weight loss aid, available since June 2007. It contains 60 mg of orlistat, which blocks the absorption of about 25% of dietary fat. Clinical studies have shown that users of Alli can lose up to 50% more weight than through dieting alone, with 81% of participants reporting satisfaction and 91% reporting weight loss after 90 days. The drug has a well-documented safety and efficacy profile from over 100 clinical studies and is recommended for adults with a BMI of 28 or more, to be taken three times a day with meals containing fat. For more information, visit the GlaxoSmithKline Alli press release.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of orlistat, contributing significantly to the global market. In 2024, the global orlistat market size was estimated at USD 3152.2 million, with Teva being one of the key players. The market is projected to grow at a CAGR of 6.1% from 2024 to 2031, driven by increasing demand for weight management solutions. Teva's presence in regions like North America, Europe, and Asia Pacific helps in catering to a diverse consumer base seeking both prescription and over-the-counter weight loss aids. The company's strong distribution network and regulatory approvals further enhance its market position. For more information, visit the Teva Pharmaceuticals website.

Sandoz

Sandoz, a subsidiary of Novartis, is a prominent producer of orlistat, contributing significantly to the global market. In 2024, the global orlistat market, which includes Sandoz's offerings, was valued at USD 3152.2 million and is projected to grow at a CAGR of 6.1% from 2024 to 2031. Sandoz's orlistat products are available in various regions, including North America, Europe, and the Asia-Pacific, where they cater to a diverse consumer base seeking weight management solutions. The company's strong distribution channels and regulatory compliance have been key factors in its market success. Sandoz's orlistat is available in doses such as 120 mg and 60 mg, catering to different patient needs.

Actavis

Actavis is a prominent player in the orlistat market, known for its high-quality formulations that aid in weight loss by preventing fat absorption. The company's orlistat products, available in 120 mg and 60 mg doses, have been instrumental in helping patients achieve significant weight loss, with studies showing that up to 62% of orlistat-treated patients can lose at least 10% of their baseline body weight within a year. Actavis's strategic market presence and well-planned business strategies have helped the company occupy a significant share in the global orlistat market, which was valued at USD 3.02 Billion in 2021 and is projected to reach USD 4.61 Billion by 2028, growing at a CAGR of 6.2%. The company's products are widely distributed across various regions, including North America, Europe, and Asia-Pacific, contributing to the market's overall growth. Actavis's commitment to regulatory compliance and innovative product development further solidifies its position as a leading producer of orlistat. For more information, visit their orlistat product page.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd. is a prominent player in the orlistat market, known for its high-quality formulations and widespread distribution. The company contributes significantly to the global orlistat market, which grew from $2.85 billion in 2023 to $3.03 billion in 2024 at a CAGR of 6.4%. Sun Pharmaceutical Industries Ltd. is part of a diverse group of key competitors, including Merck & Co. Inc., Sanofi SA, and GlaxoSmithKline plc, driving the market's robust growth. The company's products are available in various regions, with North America holding around 40% of the global revenue and the Asia-Pacific region exhibiting the highest growth rate. As the market is projected to reach $3.91 billion by 2028, Sun Pharmaceutical Industries Ltd. is well-positioned to continue its strong presence.

Torrent Pharmaceuticals

Torrent Pharmaceuticals is a prominent player in the orlistat market, known for its high-quality and effective weight management solutions. The global orlistat market, which includes contributions from Torrent Pharmaceuticals, is projected to grow from $2.85 billion in 2023 to $3.03 billion in 2024 at a CAGR of 6.4%, and is expected to reach $3.91 billion by 2028. In 2024, the global orlistat market size is estimated at USD 3,152.2 million, with North America holding over 40% of the global revenue. The market's growth is driven by increasing awareness of obesity-related health risks and the availability of orlistat in lower doses over-the-counter. Torrent Pharmaceuticals benefits from this trend, catering to a diverse consumer base seeking both prescription and non-prescription weight loss aids.

Aurobindo Pharma

Aurobindo Pharma is a leading producer of orlistat, known for its commitment to delivering high-quality, affordable generic pharmaceuticals. The company has expanded its portfolio to include over 125 product families and 450 individual product packages, with a significant presence in the US market where it generates 48% of its revenue from U.S. drug formulations as of FY 2024. Aurobindo Pharma's vertical integration, including extensive capacities in active pharmaceutical ingredients and finished dosage forms, enables it to maintain high standards in manufacturing orlistat and other medications. The company's focus on quality, affordability, and customer satisfaction has positioned it as one of the top generic pharmaceutical companies globally. Aurobindo's recognition as the fastest growing pharmaceutical company in 2012 and its continued growth underscore its excellence in the industry. For more information, visit their official website.

Mylan

Mylan is a prominent producer of orlistat, contributing significantly to the global market which was valued at USD 3.03 billion in 2024 and is projected to grow at a CAGR of 6.4% from 2024 to 2033. Mylan's orlistat, often marketed under the brand name Alli for over-the-counter sales, captures a substantial share of the market, particularly in regions like North America where the orlistat market size was USD 1.26 billion in 2024. The drug's effectiveness in preventing fat absorption has made it a popular choice for weight management, driving its robust growth. With a diverse consumer base and strong distribution channels, Mylan's orlistat continues to be a key player in the obesity treatment market. The increasing prevalence of obesity and related health concerns further solidify Mylan's position in the market.

Cipla

Cipla, a renowned pharmaceutical company, is a significant producer of orlistat, a medication designed to treat obesity by inhibiting fat absorption. The orlistat market, which includes Cipla's offerings, is projected to grow from $2.85 billion in 2023 to $3.03 billion in 2024 at a CAGR of 6.4%, and is expected to reach $3.91 billion by 2028 with a CAGR of 6.5%. Cipla's orlistat products are available in various doses, including 120 mg and 60 mg, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. The company's commitment to quality and regulatory compliance has contributed to the strong growth in the orlistat market. With increasing healthcare spending on obesity treatments and government programs promoting weight loss, Cipla's orlistat remains a vital component in the anti-obesity medication landscape.